Tempol is under clinical development by Matrix Biomed and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Glioblastoma Multiforme (GBM) have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tempol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tempol overview
Tempol is under development for the radiation-induced skin toxicity, prevention of radiation-induced oral mucositis, chemotherapy-induced toxicities, treatment of ataxia-telangiectasia (Louis-Bar syndrome), recurrent glioblastoma multiforme, prostate cancer, doxorubicin induced toxicities, macular degeneration, cisplatin toxicities and paclitaxel induced toxicities. The drug candidate is administered orally and topically as a capsule and as a gel. MTS-01 (Tempol) is a piperidine nitroxide. Tempol is a membrane-permeable radical scavenger. It acts by targeting HIF-1 and HIF-2. It was under development for the treatment of alopecia and depression.
It was under development for the treatment of ARDS, cytokine storm due to COVID-19 disease, ataxia telangiectasia, radiation induced dermatitis and peripheral neuropathy
Matrix Biomed overview
Matrix Biomed is a biopharmaceutical company focused on the development of novel gene-based therapeutics for cancer treatments. The company developed TEMPOL, a compound that used to treat anthracyclines and platinum Induced toxicity. Its pipeline products include MTS-01, for the prevention of radiation dermatitis, MTS-10, for the prevention of oral mucositis. The organization’s pipeline products also include MBM-01, for the treatment of ataxia telangiectasia, glaucoma, and cisplatin and radiation-induced toxicities and MBM-02, for the treatment of prostate cancer, glioblastoma multiforme, and cerebral cavernous malformations. . Matrix Biomed is headquartered in Irvine, California, the US.
For a complete picture of Tempol’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
